EN DE
Watch RPG Life Sciences Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

RPG Life Sciences Limited (RPGLIFE) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of RPG Life Sciences Limited stock ₹436, price ₹2,578, that is 83.1% below the price, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE105J01010

RL RPG Life Sciences Limited logo Thin data Nov 11, 2026

RPG Life Sciences Limited

RPGLIFE · NSE

Far too expensive (fair value 83% below the price) and company just short of the bar, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Solidly profitable · 16.3% net margin (TTM) 
Low debt 
Revenue last quarter +16% vs. a year ago. 
Quality 52/100 
Expensive Growth (revenue 5y +13.0 %/yr in INR) 
Mixed vs. peers (6/13) 
Wide moat 71/100 · thin data
Fair value ₹435.85 · Strongly overvalued 
Negative free cash flow 
Thin data 
Extreme value
Watch RPG Life Sciences Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹3,089 ₹433.95 Fair Value ₹435.85 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range ₹433.95 – ₹3,089 · fair‑value band ₹349.91 – ₹622.98 · the ₹2,578 price screens above the ₹435.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 11, 2026.

Follow RPG Life Sciences in your weekly email

Every Wednesday you see whether RPG Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.

Show moreShow less

The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc.

It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc.

The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.

Stock analysis

RPG Life Sciences Limited (RPGLIFE) currently trades at ₹2,578, while our model-based Fair Value estimate is ₹435.85, 83% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹1,372 per share, and 0 of the 17 models we run sit above the ₹2,578 price.

Bear case: the Asset-Based group reads lowest at ₹224.72, and 17 of the 17 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹349.91 (bear) to ₹622.98 (bull), the price of ₹2,578 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

RPG Life Sciences Limited reported revenue of ₹7.1B in FY2026 versus ₹4.4B in FY2022, a compound +12.8%/yr. Reported net income was ₹1.2B in FY2026, compounding +22.3%/yr from FY2022.

Key figures

Market cap ₹42.6B (≈ $452M) Small · P/E ratio 35.6 · P/S ratio 5.81 · EPS (TTM) ₹72.34 · Dividend yield 0.9% · Net margin 16.3% · Return on equity 20.3% · Return on assets (EBIT) 25.3% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 48% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −83%, RPGLIFE screens richer than that median.

Fair Value models

Bear ₹349.91 Fair Value ₹435.85 Bull ₹622.98
Price ₹2,578 · Downside -83.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹45.58 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings ₹250.75 ₹322.73 ₹419.49 78
Residual Income ₹349.91 ₹435.85 ₹622.98 75
EPV ₹448.80 ₹485.73 ₹515.15 74
All 17 models by family
DCF Models
Owner Earnings ₹250.75 ₹322.73 ₹419.49 78
Earnings-Based
Graham-Dodd ₹473.52 ₹2,070 ₹2,832 64
Lynch FV ₹658.17 ₹940.24 ₹1,222 61
PEG = 1.0 ₹658.17 ₹940.24 ₹1,222 57
EPV ₹448.80 ₹485.73 ₹515.15 74
Dividend Discount
Gordon GGM ₹152.92 ₹243.46 ₹304.64 69
DDM Multi-Stage ₹152.92 ₹236.64 ₹262.96 67
Multiples
P/E Multiple ₹1,149 ₹1,532 ₹1,915 63
P/S Multiple ₹887.85 ₹1,184 ₹1,480 58
P/B Multiple ₹1,077 ₹1,436 ₹1,795 55
EV/EBIT ₹1,072 ₹1,395 ₹1,718 66
EV/EBITDA ₹1,038 ₹1,349 ₹1,660 67
EV/Revenue ₹794.85 ₹1,091 ₹1,387 54
Asset-Based
NCAV (Graham) ₹148.32 ₹224.72 ₹280.90 54
Economic Profit
Residual Income ₹349.91 ₹435.85 ₹622.98 75
ROIC Compounder ₹468.25 ₹539.39 ₹620.25 72
Growth Earnings
Growth-Adj P/E ₹907.20 ₹1,296 ₹1,685 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 52/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 71
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 96
Debt, balance sheet and risk of trouble
Investment 20
Does it invest with discipline instead of growing at any price?
Low Volatility 68
How calm the share price moves, does not count
Price momentum 48
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 53
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
Start year 2021 (pandemic). Over 10 years: +9.8% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+24.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.6%
Dividend (yield on the price)0.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.6% vs 25.8%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 18%
Pace: the 5-year rate starts in 2021 (pandemic)

RPGLIFE screens overvalued: fair value 83% below the price. Compare with Merck KGaA →

Compare RPG Life Sciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −83.1% · Bottom 25%
Profitability
Return on equity (12 months) 20.3% · Top 25%
Return on assets 14.5% · Top 25%
Net margin (12 months) 16.3% · Top 25%
Operating margin (12 months) 19.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 15.8% · Above median
Dividend yield (12 months) 0.9% · Below median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 35.6× · Pricier than median
P/B 7.04× · Priciest 25%
P/S (12 months) 5.81× · Priciest 25%
EV/EBITDA 26.5× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)79 · sector 29
PAST (return on equity)81 · sector 26
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)17 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs RPGLIFE
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs RPGLIFE
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs RPGLIFE
Haleon plc HLN $9.17 $8.47 −8% vs RPGLIFE
Merck KGaA MRK €149.70 €108.83 −27% vs RPGLIFE
Galderma Group GALD CHF 191.00 CHF 112.30 −41% vs RPGLIFE
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs RPGLIFE
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs RPGLIFE
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs RPGLIFE
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs RPGLIFE

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

RPG Life Sciences Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "RPG Life Sciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/RPGLIFE

Frequently asked questions

Is RPG Life Sciences Limited (RPGLIFE) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ₹435.85 versus a price of ₹2,578, about 83% lower (overvalued).
What is the fair value of RPGLIFE?
Our model-based fair value for RPG Life Sciences Limited is ₹435.85 (as of Nov 11, 2026), built from audited fundamentals. The current price: ₹2,578.
What is the quality score of RPGLIFE?
RPG Life Sciences Limited has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RPG Life Sciences Limited (RPGLIFE)?
Our model-based price target is the fair value of ₹435.85 (as of Nov 11, 2026) from 17 valuation models. Cautious scenario ₹349.91, optimistic scenario ₹622.98. It is a calculation from audited fundamentals, not an analyst target.
What is the RPG Life Sciences Limited stock forecast for 2026?
Our models put fair value at ₹435.85, about 83% lower versus a price of ₹2,578 (overvalued). Cautious scenario ₹349.91, optimistic scenario ₹622.98. The calculation is refreshed regularly with new filings.
What is the revenue of RPG Life Sciences Limited (RPGLIFE)?
RPG Life Sciences Limited reported trailing-twelve-month revenue of about ₹7.3B (latest available figure, as of Nov 11, 2026).
Does RPG Life Sciences Limited pay a dividend?
RPG Life Sciences Limited currently shows a dividend yield of 0.87% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of RPG Life Sciences Limited (RPGLIFE)?
RPG Life Sciences Limited has a dividend yield of 0.9%.
What is the intrinsic value of RPG Life Sciences Limited (RPGLIFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RPG Life Sciences Limited it is ₹435.85 per share (as of Nov 11, 2026), against a price of ₹2,578. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is RPG Life Sciences Limited stock overvalued or undervalued in 2026?
As of Nov 11, 2026, RPGLIFE trades above its calculated fair value: price ₹2,578, fair value ₹435.85, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RPGLIFE?
No. The price is what the market pays today (₹2,578); the fair value is what the company's own numbers justify (₹435.85). For RPG Life Sciences Limited the two are ₹2,142 per share apart. That gap is exactly why we show both numbers side by side.
How much is RPG Life Sciences Limited worth?
The market values RPG Life Sciences Limited at about ₹42.6B (market capitalisation, as of Nov 11, 2026). Per share that is ₹2,578; our models calculate a fair value of ₹435.85 per share.
What do the bullish and bearish scenarios say about RPGLIFE?
Our models span a range for RPG Life Sciences Limited: cautious scenario ₹349.91, base ₹435.85, optimistic ₹622.98 per share (as of Nov 11, 2026, price ₹2,578). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RPGLIFE?
RPG Life Sciences Limited trades at a price-to-earnings ratio of 35.6 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹435.85 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 23.6. Other multiples: P/B 7.0, P/S 5.8, EV/EBITDA 26.5.
How solid is the balance sheet of RPG Life Sciences Limited (RPGLIFE)?
Balance-sheet figures for RPG Life Sciences Limited (as of Nov 11, 2026): return on equity 20.3%, debt of 0.02 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is RPGLIFE from its 52-week high?
RPG Life Sciences Limited trades at ₹2,578, about 17% below its 52-week high of ₹3,089 and 48% above the low of ₹1,744 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹435.85 is for.
Which stocks are comparable to RPG Life Sciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RPG Life Sciences Limited stock attractive at the current price?
The data as of Nov 11, 2026: price ₹2,578, calculated fair value ₹435.85 (−83%), Quality Score 52/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RPGLIFE calculated?
We run RPG Life Sciences Limited through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹435.85 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. RPG Life Sciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RPG Life Sciences Limited (RPGLIFE)?
The closing price on Nov 16, 2026 was ₹2,578. Our model-based fair value is ₹435.85, about 83% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RPG Life Sciences Limited right now?
The price sits above even our optimistic bull case (₹622.98). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of RPG Life Sciences Limited (RPGLIFE) come from?
Earnings per share at RPG Life Sciences Limited grew 31.4 % a year from 2015 to 2026. Broken into its drivers: revenue per share +9.9 %, EBIT margin +23.5 %, tax rate −1.9 %, residual (interest, one-offs) −1.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of RPG Life Sciences Limited

How large is the market capitalisation of RPG Life Sciences Limited (RPGLIFE)?
The market capitalisation of RPG Life Sciences Limited is ₹42.6B (≈ $452M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of RPG Life Sciences Limited (RPGLIFE)?
The price-to-sales ratio of RPG Life Sciences Limited is 5.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of RPG Life Sciences Limited (RPGLIFE)?
Earnings per share at RPG Life Sciences Limited are ₹72.34 (price ÷ EPS = P/E 35.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of RPG Life Sciences Limited (RPGLIFE)?
The dividend yield of RPG Life Sciences Limited is 0.9% (payout 31.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of RPG Life Sciences Limited (RPGLIFE)?
The net margin of RPG Life Sciences Limited is 16.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RPG Life Sciences Limited (RPGLIFE)?
The return on equity (ROE) of RPG Life Sciences Limited is 20.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RPG Life Sciences Limited (RPGLIFE)?
On an EBIT basis the return on assets of RPG Life Sciences Limited is 25.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of RPG Life Sciences Limited (RPGLIFE)?
The operating margin of RPG Life Sciences Limited is 19.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at RPG Life Sciences Limited (RPGLIFE)?
Revenue at RPG Life Sciences Limited is growing 15.8% versus a year earlier (3y avg +11.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at RPG Life Sciences Limited (RPGLIFE)?
Earnings per share at RPG Life Sciences Limited are growing 17.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does RPG Life Sciences Limited (RPGLIFE) generate?
The free cash flow of RPG Life Sciences Limited is −₹800K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does RPG Life Sciences Limited (RPGLIFE) hold?
RPG Life Sciences Limited holds more cash than debt, ₹1.7B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch RPG Life Sciences Limited in the live analysis

One click puts RPG Life Sciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.